CIDARA THERAPEUTICS, INC.

Profile

Company Names

CIDARA THERAPEUTICS, INC.
K2 THERAPEUTICS, INC.

Addresses

6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA 92121

6310 NANCY RIDGE DRIVE, SAN DIEGO, CA 92121

Phone Numbers

858-752-6170
781-314-1105

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2012

State Incorporated:

DELAWARE

Total Amount Raised:

$318,751,143.00

Number of Funding Rounds:

6
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
6
2024-04-24 
$240,000,000.00 
$240,000,000.00 
$0.00 
Equity 
5
2019-09-03 
$9,008,173.00 
$9,008,173.00 
$0.00 
Equity 
4
2018-05-23 
$1,562,499.00 
$1,874,999.00 
$312,500.00 
 
3
2017-10-24 
$20,160,000.00 
$20,160,000.00 
$0.00 
Equity 
2
2015-02-10 
$42,019,999.00 
$42,019,999.00 
$0.00 
Equity 
1
2014-05-30 
$6,000,472.00 
$6,000,472.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
NEIL 
 
ABDOLLAHIAN 
EXECUTIVE OFFICER
KEN 
 
BARTIZAL 
EXECUTIVE OFFICER
BONNIE 
 
BASSLER, PH.D. 
DIRECTOR
DAN 
 
BURGESS 
DIRECTOR
DANIEL 
BURGESS 
DIRECTOR
DANIEL 
D. 
BURGESS 
DIRECTOR
CARIN 
 
CANALE-THEAKSTON 
DIRECTOR
PAUL 
 
DARUWALA 
EXECUTIVE OFFICER
TIMOTHY 
FRANSON 
DIRECTOR
DAVID 
 
GOLLAHER 
DIRECTOR
KEVIN 
 
JUDICE 
EXECUTIVE OFFICER, DIRECTOR
JAMES 
 
LEVINE 
EXECUTIVE OFFICER
JAMES 
 
MERSON, PH.D. 
DIRECTOR
CHRYSA 
 
MINEO 
DIRECTOR
JESSICA 
 
OIEN 
EXECUTIVE OFFICER
MATTHEW 
 
ONAITIS 
EXECUTIVE OFFICER
ROBERT 
PEREZ 
DIRECTOR
SCOTT 
ROCKLAGE 
DIRECTOR
TAYLOR 
 
SANDISON 
EXECUTIVE OFFICER
TAYLOR 
 
SANDISON, M.D. 
EXECUTIVE OFFICER
TED 
 
SCHROEDER 
DIRECTOR
THEODORE 
SCHROEDER 
DIRECTOR
PREETAM 
 
SHAH, PH.D. 
EXECUTIVE OFFICER
RYAN 
 
SPENCER 
DIRECTOR
JEFFREY 
 
STEIN 
EXECUTIVE OFFICER, DIRECTOR
JEFFREY 
 
STEIN, PH.D. 
EXECUTIVE OFFICER, DIRECTOR
LAURA 
 
TADVALKAR, PH.D. 
DIRECTOR
LESLIE 
 
TARI, PH.D. 
EXECUTIVE OFFICER
DIRK 
 
THYE 
EXECUTIVE OFFICER
SHANE 
 
WARD 
EXECUTIVE OFFICER
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
D
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2024-04-24 
D
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2019-09-03 
D
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
 
2018-05-23 
D
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2017-10-24 
D
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2015-02-10 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2014-05-30 
D
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2014-05-30 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#